Artelo Biosciences, Inc.
ARTL
$1.04
$0.010.97%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 1.34M | 870.00K | 827.00K | 1.08M | 1.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.81M | 1.20M | 2.51M | 2.59M | 3.24M |
| Operating Income | -3.81M | -1.20M | -2.51M | -2.59M | -3.24M |
| Income Before Tax | -3.78M | -1.13M | -2.43M | -2.48M | -3.07M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -3.78M | -1.13M | -2.43M | -2.48M | -3.07M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -3.78M | -1.13M | -2.43M | -2.48M | -3.07M |
| EBIT | -3.81M | -1.20M | -2.51M | -2.59M | -3.24M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -1.16 | -0.35 | -0.75 | -0.78 | -0.97 |
| Normalized Basic EPS | -0.73 | -0.23 | -0.49 | -0.51 | -0.64 |
| EPS Diluted | -1.16 | -0.35 | -0.75 | -0.78 | -0.97 |
| Normalized Diluted EPS | -0.73 | -0.23 | -0.49 | -0.51 | -0.64 |
| Average Basic Shares Outstanding | 3.25M | 3.23M | 3.23M | 3.20M | 3.18M |
| Average Diluted Shares Outstanding | 3.25M | 3.23M | 3.23M | 3.20M | 3.18M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |